Novel 5-point 18-FDG-PET/CT visual scoring system for assessing treatment response in patients with oesophageal or gastro-oesophageal junction carcinoma.
Carcinoma, Squamous Cell
Esophageal Neoplasms
/ diagnostic imaging
Esophagogastric Junction
/ diagnostic imaging
Fluorodeoxyglucose F18
Humans
Positron Emission Tomography Computed Tomography
Prognosis
Radiopharmaceuticals
Reproducibility of Results
Retrospective Studies
Stomach Neoplasms
/ diagnostic imaging
metabolic response
oesophagus
positron emission tomography
primary visual score
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
08
02
2020
revised:
09
08
2020
accepted:
05
09
2020
pubmed:
17
10
2020
medline:
6
11
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
The purpose of this study was to investigate the prognostic utility and reproducibility of a qualitative 5-point 18-fluorodeoxyglucose (FDG)-PET primary visual score (PVS) in patients with oesophageal and gastro-oesophageal junction (GOJ) cancer. This was a retrospective review of patients with histologically proven oesophageal or GOJ cancer who received curative intent therapy. Clinical, pathological and imaging data were extracted from electronic medical records. Patients were required to have pre-treatment and post-treatment FDG-PET scans, that were evaluated with a 5-point primary visual score (prePVS, postPVS). The changes in PVS (ΔPVS) were correlated with progression-free survival and overall survival. Interobserver variability was assessed using Cohen's Kappa intraclass correlation and agreement. Sixty-seven patients were retrospectively identified. Two (3%), 36 (54%) and 29 (43%) of the patients had stage I, II and III disease respectively. Twenty-five (37%) patients had squamous cell carcinoma. Thirty-seven (55%) patients proceeded onto surgical resection. postPVS was associated with both PFS (P = 0.013) and OS (P = 0.0002). ΔPVS predicted for PFS (P = 0.002) and OS (P = 0.0003). When thresholds of response were considered, agreement was 80.6% (K = 0.78) and 74.6% (K = 0.69) for postPVS and ΔPVS respectively. Qualitative assessment of oesophageal and GOJ cancers utilising FDG-PET is reproducible and may be able to prognosticate outcomes in patients undergoing treatment. Prospective validation is required.
Identifiants
pubmed: 33063470
doi: 10.1111/1754-9485.13110
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-37Informations de copyright
© 2020 The Royal Australian and New Zealand College of Radiologists.
Références
WHO. World Cancer. Report. 2014.
Australian Institute of Health and Welfare. Cancer in Australia 2017. 2017. Contract No.: September 22.
Rajput MY. Esophageal cancer: the changes in incidence during last years. An International Peer Reviewed Open Access Journal For Rapid Publication. 2017; 7.
Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8(3): 226-34.
Shapiro J, Van Lanschot JJB, Hulshof MC et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16(9): 1090-8.
Sjoquist KM, Burmeister BH, Smithers BM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12(7): 681-92.
van Hagen P, Hulshof M, Van Lanschot J et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22): 2074-84.
Chatterton B, Shon IH, Baldey A et al. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009; 36(3): 354-61.
Flamen P, Lerut A, Van Cutsem E et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000; 18(18): 3202-10.
Barrington SF, Mikhaeel NG, Kostakoglu L et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048.
Press OW, Li H, Schöder H et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016; 34(17): 2020.
Biggi A, Gallamini A, Chauvie S et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013; 54(5): 683-90.
Lordick F, Ott K, Krause B-J et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8(9): 797-805.
Goodman KA, Niedzwiecki D, Hall N et al. Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. J Clin Oncol 2017; 35(4_suppl): 1.
Tatsumi M, Isohashi K, Kato H, Watabe T, Hatazawa J. Application of Deauville or Hopkins visual 5-point scale in response assessment of esophageal cancer receiving neoadjuvant chemotherapy and surgery. J Nucl Med. 2017;58(Supplement 1):493.
Jeong Y, Kim JH, Kim SB et al. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. J Surg Oncol. 2014; 109(5): 472-7.
Huang Y-C, Li S-H, Lu H-I et al. Post-chemoradiotherapy FDG PET with qualitative interpretation criteria for outcome stratification in esophageal squamous cell carcinoma. PLoS One 2019; 14: e0210055.
Zhu W, Xing L, Yue J et al. Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta-analysis. The British journal of radiology. 2012; 85: e694-e701.
Hatt M, Visvikis D, Albarghach NM et al. Prognostic value of 18 F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011; 38(7): 1191-202.
Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: Response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Radiother Oncol. 2008; 89(3): 278-86.
Foley KG, Fielding P, Lewis WG et al. Prognostic significance of novel 18F-FDG PET/CT defined tumour variables in patients with oesophageal cancer. Eur J Radiol. 2014; 83(7): 1069-73.
Jayachandran P, Pai RK, Quon A et al. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys 2012; 84: 471-7.
Seok H, Kim S-J, Kim IJ, Kim K. Predictive value of metabolic tumor volume measured by 18F-FDG PET for regional lymph node status in patients with esophageal cancer. Clin Nucl Med 2012; 37: 442-6.
Downey RJ, Akhurst T, Ilson D et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003; 21: 428-32.
Westerterp M, van Westreenen HL, Reitsma JB et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 2005; 236: 841-51.
Swisher SG, Maish M, Erasmus JJ et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004; 78: 1152-60.
Levine EA, Farmer MR, Clark P et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006; 243: 472.
Flamen P, Van Cutsem E, Lerut A et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002; 13: 361-8.
Javeri H, Xiao L, Rohren E et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 2009; 115: 5184-92.
Vallböhmer D, Hölscher AH, Dietlein M et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009; 250: 888-94.
Kim MK, Ryu J-S, Kim S-B et al. Value of complete metabolic response by 18F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer. 2007; 43: 1385-91.
Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol. 2006; 78: 236-44.
Courrech Staal E, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 2010; 97: 1482-96.
Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v50-v57.
Ma J-l, Jin L, Li Y-D et al. The intensity of radiotherapy-elicited immune response is associated with esophageal cancer clearance. Journal of immunology research. 2014; 2014: 1-7.
Zschaeck S, Hofheinz F, Zöphel K et al. Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging 2017; 44: 1813-22.
Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20: 1167-74.
Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005; 23: 2310-7.
Minsky BD, Neuberg D, Kelsen DP et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. International Journal of Radiation Oncology* Biology*. Physics. 1999; 43: 517-23.
Kluge R, Chavdarova L, Hoffmann M et al. Inter-reader reliability of early FDG-PET/CT response assessment using the Deauville scale after 2 cycles of intensive chemotherapy (OEPA) in Hodgkin’s lymphoma. PLoS One 2016; 11: e0149072.
Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A. Report on the 4th international workshop on positron emission tomography in lymphoma held in Menton, France, 3-5 October 2012. Leukemia & lymphoma. 2014; 55: 31-7.
Han EJ, Joo Hyun O, Yoon H et al. FDG PET/CT response in diffuse large B-cell lymphoma: reader variability and association with clinical outcome. Medicine. 2016; 95: e4983.
Monjazeb AM, Riedlinger G, Aklilu M et al. Outcomes of patients with esophageal cancer staged with [18F]Fluorodeoxyglucose Positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 2010; 28(31): 4714-21.
Ajani JA, D’Amico TA, Bentrem DJ et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019; 17: 855-83.